Vaccine: X (Apr 2023)
Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
- Kenji Ota,
- Satoshi Murakami,
- Kaori Ishihara,
- Daisuke Sasaki,
- Tetsuya Usui,
- Fujiko Mitsumoto-Kaseida,
- Kei Sakamoto,
- Kosuke Kosai,
- Hiroo Hasegawa,
- Takahiro Takazono,
- Akitsugu Furumoto,
- Norichika Asoh,
- Hiroyuki Yoshimine,
- Toyomitsu Sawai,
- Masanari Onizuka,
- Noriaki Makimoto,
- Koichi Izumikawa,
- Hiroshi Mukae,
- Shigeru Kohno,
- Katsunori Yanagihara
Affiliations
- Kenji Ota
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan; Corresponding author at: Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1, Sakamoto, Nagasaki, Japan.
- Satoshi Murakami
- Abbott Japan LLC, Tokyo, Japan
- Kaori Ishihara
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Daisuke Sasaki
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Tetsuya Usui
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Fujiko Mitsumoto-Kaseida
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Kei Sakamoto
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Kosuke Kosai
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Hiroo Hasegawa
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Takahiro Takazono
- Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Akitsugu Furumoto
- Juzenkai Hospital, Nagasaki, Japan; Infectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, Japan
- Norichika Asoh
- Juzenkai Hospital, Nagasaki, Japan
- Hiroyuki Yoshimine
- Inoue Hospital, Nagasaki, Japan
- Toyomitsu Sawai
- Nagasaki Harbor Medical Center, Nagasaki, Japan
- Masanari Onizuka
- Nagasaki Kita Tokushukai Hospital, Nagasaki, Japan
- Noriaki Makimoto
- Tagami Hospital, Nagasaki, Japan
- Koichi Izumikawa
- Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan
- Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Shigeru Kohno
- Nagasaki University, Nagasaki, Japan
- Katsunori Yanagihara
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
- Journal volume & issue
-
Vol. 13
p. 100282
Abstract
The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.
